Kelzy

Dienogest/Ethinylestradiol, the active ingredient in Kelzy, is a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy and can help regulate menstrual cycles in women of reproductive age. It is indicated for hormonal contraception and is approved for use in the European Union.

GNH USA supplies Kelzy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across global markets. Our distribution network covers Europe, Asia, Africa and the Americas, facilitating timely access to the product.

Kelzy, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent ovulation. - Prevention of pregnancy: provides reliable hormonal contraception for women of reproductive age. - Regulation of menstrual cycle: helps achieve more predictable bleeding patterns and reduces dysmenorrhea. - Treatment of acne: reduces androgen‑driven acne severity in eligible patients. - Management of endometriosis‑associated pain: can alleviate pelvic pain symptoms. - Control of heavy menstrual bleeding: reduces volume of menstrual blood loss.

Kelzy may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Breast tenderness - Headache - Breakthrough bleeding

Serious or Rare Side Effects: - Venous thromboembolism (deep vein thrombosis, pulmonary embolism) - Severe hypertension - Liver tumor (hepatocellular adenoma)

Before prescribing Kelzy, clinicians should evaluate patient history and consider the following precautions. - Assess cardiovascular risk: review history of thrombosis, smoking status, hypertension, and obesity. - Contraindicated in estrogen‑dependent tumors: avoid use in patients with known breast or endometrial cancer. - Monitor liver function: use with caution in patients with active hepatic disease. - Review concomitant medications: enzyme‑inducing drugs may reduce contraceptive effectiveness. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Kelzy can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Potent enzyme inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce hormonal levels and increase risk of contraceptive failure. - Anticoagulants (e.g., warfarin): combined use can enhance bleeding risk. - Certain antiretrovirals (e.g., protease inhibitors): may affect hormone metabolism and reduce effectiveness.

Moderate Interactions (Monitor Closely): - Antihypertensives: may require blood pressure monitoring as hormonal changes can affect control. - Other hormonal therapies (e.g., hormone replacement therapy): may increase side‑effect burden. - Some antibiotics (e.g., macrolides, fluoroquinolones): may have variable impact on contraceptive reliability.